[
    [
        {
            "time": "2018-03-28",
            "original_text": "今日散户最关注的前50只个股（3/28）",
            "features": {
                "keywords": [
                    "散户",
                    "关注",
                    "个股"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "今日散户最关注的前50只个股（3/28）",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "复星医药：配置全球优质医疗资源买入评级",
            "features": {
                "keywords": [
                    "复星医药",
                    "全球",
                    "医疗资源",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：配置全球优质医疗资源买入评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "[审慎增持评级]复星医药(600196)年报点评：17年延续稳定增长单抗研发龙头将入收获期",
            "features": {
                "keywords": [
                    "复星医药",
                    "年报",
                    "稳定增长",
                    "单抗研发",
                    "收获期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[审慎增持评级]复星医药(600196)年报点评：17年延续稳定增长单抗研发龙头将入收获期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "[大行评级]摩通：升复星医药(02196.HK)目标价至62港元评级“增持”",
            "features": {
                "keywords": [
                    "摩通",
                    "复星医药",
                    "目标价",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[大行评级]摩通：升复星医药(02196.HK)目标价至62港元评级“增持”",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "复星医药2017年营收185.34亿元推进国际化进程",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收",
                    "国际化"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药2017年营收185.34亿元推进国际化进程",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "医药生物板块涨幅居前新天药业和科华生物等涨停",
            "features": {
                "keywords": [
                    "医药生物",
                    "涨幅",
                    "涨停"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物板块涨幅居前新天药业和科华生物等涨停",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "两大新经济主线浮出水面多路资金蜂拥买入",
            "features": {
                "keywords": [
                    "新经济",
                    "主线",
                    "资金",
                    "买入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "两大新经济主线浮出水面多路资金蜂拥买入",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "CAR-T领域中国公司集体“爆发”监管层与企业合力实现“弯道超车”",
            "features": {
                "keywords": [
                    "CAR-T",
                    "爆发",
                    "监管层",
                    "弯道超车"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CAR-T领域中国公司集体“爆发”监管层与企业合力实现“弯道超车”",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "2017年复星医药营收185.34亿元同比增长26.69%",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收",
                    "同比增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2017年复星医药营收185.34亿元同比增长26.69%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "复星医药:研发投入高速增长再次验证公司创新属性",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发投入",
                    "创新"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药:研发投入高速增长再次验证公司创新属性",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]